Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Phase 2b randomized trial of OX40 inhibitor telazorlimab for moderate-to-severe atopic dermatitis.

Autor: Rewerska B; Diamond Clinic, Krakow, Poland., Sher LD; Peninsula Research Associates, Rolling Hills Estates, Calif., Alpizar S; Clinical Research Trials of Florida Inc, Tampa, Fla., Pauser S; KliFOs-Klinische Forschung Osnabrück, Osnabrück, Germany., Pulka G; School of Medicine, Jagiellonian University Medical College, Krakow, Poland., Mozaffarian N; Ichnos Sciences, New York, NY., Salhi Y; Ichnos Sciences, New York, NY., Martinet C; Keyrus Life Science, Levallois-Perret, France., Jabert W; Ichnos Sciences, New York, NY., Gudi G; Ichnos Sciences, New York, NY., Ca V; Ichnos Sciences, New York, NY., Gn S; Glenmark Pharmaceuticals, Mumbai, India., Macoin J; Ichnos Sciences, New York, NY., Anstett V; Ichnos Sciences, New York, NY., Turrini R; Ichnos Sciences, New York, NY., Doucey MA; Ichnos Sciences, New York, NY., Blein S; Ichnos Sciences, New York, NY., Konto C; Ichnos Sciences, New York, NY., Machkova M; CCR Prague sro, Prague, Czech Republic.

Publikováno v: The journal of allergy and clinical immunology. Global [J Allergy Clin Immunol Glob] 2023 Nov 22; Vol. 3 (1), pp. 100195. Date of Electronic Publication: 2023 Nov 22 (Print Publication: 2024).